title: Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: a report of 2 cases.
abstract: Two patients with recurrent lymphoma developed an acute, transient encephalopathy following administration of recombinant human granulocyte-colony stimulating factor (rhG-CSF), filgrastim, in anticipation of leukapheresis for hematopoietic stem cell transplantation. Head magnetic resonance imaging showed evidence of blood-brain barrier (BBB) breakdown, compatible with posterior reversible encephalopathy syndrome (PRES). The proposed pathogenesis of PRES was rhG-CSF-induced neutrophil mobilization and activation with the release of inflammatory mediators, resulting in transient alteration of barrier permeability and capillary leakage.
authors: Department of Neurology and Neuroscience, Weill Cornell Medical College/New York Presbyterian Hospital, 525 East 68th Street, New York, NY 10065‐4885, USA. pstuebge@med.cornell.edu
authors: Joerg-Patrick
authors: JP
authors: Stübgen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D019788:Fluorodeoxyglucose F18; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D066298:In Vitro Techniques; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D020258:Neurotoxicity Syndromes / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology; D049268:Positron-Emission Tomography; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18; D016178:Granulocyte-Macrophage Colony-Stimulating Factor